New chemo combo aims to stop esophageal cancer from coming back
NCT ID NCT03110926
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This phase II trial is testing whether giving a chemotherapy combination called mFOLFOX6 before the usual chemoradiation and surgery can help prevent esophageal cancer from returning. The study involves 40 adults with locally advanced esophageal cancer that can be surgically removed. Researchers are measuring how many patients remain cancer-free after two years and checking for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mFOLFOX6 (a combination of chemotherapy drugs: oxaliplatin, leucovorin, and 5-fluorouracil)
What this could lead to
If successful, this approach could lower the chance of cancer returning after standard treatment for locally advanced esophageal cancer.
What could go wrong
This is a small, early-phase trial with only 40 participants, so results may not apply to everyone. Chemotherapy can cause significant side effects, and the added benefit over standard care is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Rochester
Rochester, New York, 14642, United States